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Abstract: There have been no major improvements in the overall survival of ovarian cancer patients
in recent decades. Even though more accurate surgery and more effective treatments are available,
the mortality rate remains high. Given the differences in origin and the heterogeneity of these
tumors, research to elucidate the signaling pathways involved is required. The Transforming Growth
Factor (TGFβ) family controls different cellular responses in development and cell homeostasis.
Disruption of TGFβ signaling has been implicated in many cancers, including ovarian cancer.
This article considers the involvement of TGFβ in ovarian cancer progression, and reviews the various
mechanisms that enable the TGFβ signaling pathway to control ovarian cancer cell proliferation.
These mechanistic explanations support the therapeutic use of TGFβ inhibitors in ovarian cancer,
which are currently in the early phases of development.
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1. Ovarian Cancer
Ovarian cancer has the second highest incidence of gynecological cancers (≈6 per 100,000 individuals)
and is the fifth most common cause of cancer deaths in women in western countries [1,2]. Despite
the significant advances in detection, surgical techniques and treatments, diagnosis is generally made
at an advanced stage and its mortality rate has remained fairly static in recent years. Although
early-stage disease has a good prognosis, most patients relapse after first-line treatment, for which
carboplatin-paclitaxel is the standard of care. The global five-year survival rate is 42% for early-stage
disease, dropping to 29% in advanced-stage disease [3].
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One of the reasons for this low survival rate is the advanced stage at time of diagnosis with
disseminated peritoneal disease. Another is the diversity of tumor types classified as ovarian cancer on
the basis of their common anatomical location. In fact, ovarian tumor subtypes are essentially different
diseases and their histological and molecular characteristics are remarkably heterogeneous. Thus,
ovarian cancer can be divided into germ cell (3%), sex-cord stroma (2%) and epithelial (95%) tumors.
Moreover, epithelial tumors can be subdivided into five main histotypes entirely on the basis of their
tumor cell morphology, according to the predominant pattern of differentiation: low-grade serous
carcinoma (LGSC, prevalence less than 5%), high-grade serous carcinoma (HGSC, 68%), endometrioid
carcinoma (EMC, 20%), clear-cell carcinoma (CCC, 4%) and mucinous carcinoma (MC, 3%) [4]. Despite
these differences, the same treatment is employed for all histological subtypes of ovarian cancer [5]. In
order to increase the ovarian cancer survival rate, it is necessary to study the carcinogenesis process in
all ovarian cancer types. One of the approaches is to identify the involvement of different signaling
pathways in the transformation process of the various ovarian tumor types. Of these signaling
pathways, TGFβ signaling could play an important role in ovarian tumor progression.
2. The Highly Discrepant Literature about the Origin of Ovarian Cancer
An ovarian carcinoma can originate from various cell types, giving rise to different tumor
subtypes. Germ cells, which develop into germ cell tumors (dysgerminomas, yolk sac tumors and
immune teratomas), represent only 3% of all ovarian cancers, while sex cord-stromal tumors (1–2% of
ovarian cancers) are generated from granulosa-theca cells, which produce estrogen and progesterone.
Nevertheless, more than 90% of ovarian tumors are localized on the epithelial surface, have an epithelial
histology and are therefore called epithelial ovarian cancers (EOCs).
The cell of origin in the case of epithelial ovarian tumors is a controversial topic, and several
theories have been proposed. It was originally widely believed that these tumors originated from
the ovarian surface epithelium (OSE) and differentiated into the various tumor histological subtypes.
Another theory was that the ovarian tumors were derived from a Müllerian-type tissue (columnar
epithelium, often ciliated) in the paraovarian and paratubal locations [6]. Although an ovarian origin
cannot be discounted, new evidence demonstrates that some supposedly primary ovarian cancers
actually originate in other pelvic organs, such as the digestive tract, and only secondarily in the ovary.
This is the case for the majority of mucinous carcinomas, which are metastases from extraovarian
sites [7–9].
In recent years, it has been proposed that some EOCs originate from precursor epithelial lesions
in the distal, fimbriated end of the Fallopian tube [10–13]. Other ovarian tumor types originate from
ovarian endometriosis, through the process of retrograde menstruation and endometriosis generated
after neoplastic transformation of tubal origin [9,13–15]. Recently, Eckert and colleagues analyzed the
genetics of different HGSC samples and discovered that cancer cells located in the Fallopian tube,
which were considered to have initiated the ovarian cancers, were actually metastases of the ovarian
tumor [16]. These discoveries call into question the theory of the precursor lesions in the fimbriated
Fallopian tube, at least in this cancer type. Therefore, more research has to be done in order to gain a
deeper understanding of the mechanism causing these morphological transformations during cancer
progression, and thereby to develop a tool that improves the chances of better detection and treatment.
At the genetic level, the p53 gene has been implicated in the formation of EOC. This was one of
the first mutations to be observed, and is the most prevalent in this tumor type, and in retinoblastoma
(Rb) [17,18]. It has also been demonstrated that, in the case of clear cell carcinoma, concomitant
mutations of ARID1A and PIK3CA are necessary to initiate tumor formation [19]. Other signaling
pathways implicated include that for the receptor tyrosine kinases c-Met and Ron, which are thought
to play a role in ovarian cancer initiation and progression [20]. Thus, it is important to identify the
main signaling pathways in normal ovarian cells, and to determine how they are altered to give rise to
ovarian cancer.
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3. TGFβ Transforming Growth Factor) Member Signaling Occurs in Normal Ovary
Members of the TGFβ superfamily are key factors in follicle development, regulating
bi-directional communication between ovarian cell types (oocyte, granulosa or theca cells) [21]. TGFβ
superfamily ligands bind to TGFβ receptors type I (TGFβRI) and type II (TGFβRII), transmembrane
serine-threonine kinases specific for each ligand. After ligand binding, both receptors form a
heterodimeric complex in which type II receptor phosphorylates and activates the type I component.
In turn, active type I receptor phosphorylates SMA and mothers against decapentaplegic homologs
(SMADs), transcription factors that translocate to the nucleus where they regulate the expression of
target genes in collaboration with other transcriptional partners. TGFβ superfamily members, such as
activins and bone morphogenetic proteins (BMP) members, have been implicated in mammal ovary
functionality during oocyte maturation and in regulating follicle development [22,23]. In contrast,
less is known about other TGFβ family members, such as the TGFβ sub-family. All three TGFβ
ligand isoforms (TGFβ 1, 2 and 3) have been detected in normal ovarian epithelium [24], although
little is known about their functionality. We have observed by immunodetection of active SMAD2
(phosphorylated and accumulated in the nuclei) in paraffin-embedded samples that the TGFβ signaling
pathway is active in normal Fallopian tube epithelium (Figure 1A) [25]. Li and colleagues observed
that SMAD2 and SMAD3 are essential for normal follicle development and oocyte maturation in order
to produce developmental competence [26]. In consequence, the TGFβ superfamily is a fundamental
component of a key signaling pathway in normal ovarian cells that could also be important in ovarian
cancer when it is dysregulated.
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between pSMAD2 levels in tissue microarray from high-grade serous ovarian patients and overall
patient survival. The tissue microarray (TMA) comprised triplet cores from ovarian tumors resected
between 1992 and 2007 at the Bellvitge Hospital (Barcelona, Spain). The study protocol was cleared by
the hospital’s Ethics Committee and signed informed consent was obtained from each patient. A total
of 27 high-degree serous paraffin-embedded epithelial ovarian tumor specimens were represented and
available for analysis on the TMA. All patients were treated using primary surgery and samples were
collected before any radiotherapy or chemotherapy. This study included patients aged 30–88 years,
with 79% aged 50–70 years. We observed no segregation due to age in our parameters. The Pearson
correlation coefficient was used for statistical analysis.
4. TGF-β and Ovarian Cancer
A key objective of ovarian cancer research is to determine which signaling pathways are involved
in its progression, with the aim of finding new therapies to reduce its high relapse rate. Focusing
on the TGFβ family members, in granulosa cells depletion of FOXO1/3 and PTEN increase levels
of activin (INHβB) and elevated phosphorylation/activation of SMAD2/3, effects that prevent
differentiation and promote granulosa cell proliferation and tumor formation [27]. Another example
of the involvement of the TGFβ family in ovarian cancer development is BMP/SMAD1/5/8 signaling,
whereby double SMAD1 and SMAD5 or triple SMAD1, 5 and 8 conditional knockout in mice generates
metastatic granulosa cell tumors [28]. Recent work by our group highlights the TGFβ signaling
pathway as a key contributor to this progression [25]. Thus treatment with a TGFβRI&II dual inhibitor,
LY2109761, inhibits ovarian cancer cell proliferation and causes a reduction in tumor size. Our results
indicate the presence of high levels of nuclei stained with active phosphoSMAD2 in tumoral cells ([25]
and Figure 1B).
TGFβ signaling is important in a wide range of cellular processes from the physiological and
pathological points of view. It is widely believed that TGFβ switches its role from tumor suppressor in
normal cells to tumor promoter in advanced cancers, favoring invasiveness and metastasis depending
on the tumor stage [29]. While TGFβ blocks cell growth in normal ovarian epithelial cells, in 40% of
ovarian carcinomas TGFβ loses its cytostatic effect but maintains epithelial mesenchymal transition
(EMT) induction and the production of extracellular matrix [30]. This loss of the TGFβ cytostatic effect
could be due to mutations in important genes in its pathway. Unlike other tumor types, inactivating
mutations in the TGFβ signaling pathway in ovarian cancer are rare and most of those that have
been found are associated with chromosomal instability [31]. In the case of SMAD4, its mutations
are not observed in ovarian tumors, but in ovarian cancer cell lines with metastatic potential. Its
expression was reduced simultaneously with the dysregulation of p21 and c-Myc expression in ovarian
tumor samples [31]. Furthermore, an allele of TGFBR1 has been linked with a high-frequency and
low-penetrance tumor susceptibility allele that predisposes to ovarian, breast and colorectal cancer,
as well as to hematological malignancies [32].
Even though not many mutations are known in ovarian cancer cells, it is clear that the TGFβ
signaling pathway is broadly active in ovarian cancer, as observed by high levels of pSMAD2 staining in
different ovarian tumor types, and that its stimulation is important for ovarian cancer progression [25].
To confirm these results, we studied pSMAD2 expression in 27 human high-grade serous ovarian
cancer patient samples and correlated its levels with overall survival. As shown in Figure 1C, a high
level of pSMAD2 staining was significantly correlated with shorter survival in these patients. Our
results concord with those of other studies obtained from independent advanced high-grade serous
ovarian cancer patient series, in which it has also been described that a high level of pSMAD2 staining
is correlated with poor patient outcome [33,34].
Mechanisms for activating the TGFβ pathway in tumors include overexpression of
microRNA-181a, repression of the negative regulator SMAD7 [33] and the autocrine/paracrine
secretion of TGFβ family members by tumoral or stromal cells [35,36]. There are three isoforms
of the TGFβ sub-family ligands, TGFβ1, TGFβ2 and TGFβ3, which share the same receptor complex
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and signal in similar ways, but vary in expression levels depending on the tissue. All three isoforms
have been observed in ovarian cancer patient samples [37,38] and linked to increased ovarian cancer
progression and metastasis [38,39]. In fact, a low level of TGFβ1 mRNA expression in advanced
ovarian tumors was associated with better prognosis [40]. A skin carcinogenesis study suggested
differential functions for each TGFβ isoform in epidermal carcinogenesis: TGFβ1 was associated with
a more differentiated state, TGFβ2 was associated with highly malignant and invading cells, and
TGFβ3 was linked to tumor stroma [41]. In addition, TGFβ isoforms are differentially expressed by
OSE cells, and TGFβ seems to play an important role in regulating epithelial cell homeostasis and
possibly stromal–OSE interactions [24]. Therefore, more work needs to be done to establish which
TGFβ ligand is playing a role in tumor progression, whether there are differences between tumor and
stromal cell types, and the implications of each TGFβ ligand for ovarian cancer progression. In any
case, the TGFβ signaling pathway is highly activated in ovarian tumors reinforcing the idea of its
potential importance in ovarian cancer.
5. TGFβ Controls Proliferation of Ovarian Cancer Cells
TGFβ blocks cell growth in normal ovarian epithelial cells but its effect on ovarian cancer cells
remains controversial. For instance, it was demonstrated that proliferation was not inhibited after the
addition of TGFβ in primary ovarian carcinoma cells, in contrast with its inhibitory effect on normal
human OSE cells [42]. In two ovarian carcinoma cell types (OVCCRI and IGROVI) a different effect
of TGFβ has been observed, in which TGFβ1 could induce cell cycle arrest at the G1/S transition in
OVCCRI but not in IGROVI cells. The conclusion from this is that TGFβ growth inhibition is not a
general feature of all ovarian cancer cells [43].
The mechanism responsible for the block of the anti-proliferative action of TGF-β remains unclear.
The involvement of different components of the TGFβ signaling pathway has been examined in
tissues of epithelial ovarian cancer patients and ovarian tumoral cell lines [44]. No modifications of
TGFβ1 levels, its receptors or SMAD2/3 proteins were observed in either case. Therefore, the authors
proposed that a failure had arisen in the control of the cell cycle by downstream molecules of the
TGFβ signaling cascade. Likewise, Baldwin and colleagues concluded that TGFβ signaling remained
functional, with the correct induction of some gene responses in primary ovarian carcinoma cells [42].
In contrast, other TGFβ-induced responses, such as the induction of c-Myc, were lost when they
compared ovarian cancer cells and the human ovarian surface epithelium cells, in parallel with the
failure to block the cell cycle [42].
Recent work by our group has demonstrated that TGFβ positively controls ovarian cancer
proliferation through the control of insulin like growth factor 1 receptor (IGF1R) expression levels in
some orthotopic mouse models (PDX) and ovarian cancer cell lines [25]. We also found a correlation
between the levels of pSMAD2 and of IGF1R expression in the same patient tumor. IGF1R is a
tyrosine kinase receptor already implicated in the control of ovarian cancer cell proliferation [45].
Similar indirect mechanisms of control of cell growth and proliferation by TGFβ through other growth
factors have been described, for example, in glioma models, where TGFβ stimulates production of
platelet derived growth factor-B (PDGF-B) and activation of platelet derived growth factor receptor
β (PDGFRβ) [46]. Another mechanism involved is the expression of epidermal growth factor (EGF),
which inhibits the TGFβ anti-proliferative effect in primary ovarian cancer cells [47]. Recently,
androgens have been linked to the control of proliferation by TGFβ. Directly, or as a consequence of an
androgen-induced reduction in TGFβ receptors, these cause the inhibition of a TGFβ anti-proliferative
response [44]. Furthermore, ubiquitin specific protease 22 (USP22), high levels of which are associated
with EOC and poor prognosis, have been shown to regulate the cell cycle pathway downstream of
TGFβ1, consequently stimulating ovarian cancer cell proliferation [48]. It is not the first time that
deubiquitinating enzymes (DUBs) have been found to regulate TGFβ signaling in order to control
proliferation and other cellular processes. These include ubiquitin-specific peptidase 15 (USP15) in
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glioblastoma [49], USP11 in the TGFβ-induced EMT process [50], and ubiquitin-specific protease 4
(USP4) that participates in the crosstalk between the TGFβ and AKT signaling pathways [51].
Together, these results lead to the proposition that TGFβ signaling controls cell proliferation
through distinct, direct or indirect mechanisms in ovarian cancer.
6. Therapeutic Approaches
Although progress has been made in the treatment of ovarian cancer by way of improved surgical
debulking techniques and the introduction of platinum-taxane regimens, the overall five-year survival
rate is only 29% in advanced-stage disease [3]. Furthermore, 80% of advanced stages will relapse,
mainly in the first 18–24 months, after primary treatment. The efficacy of chemotherapy in EOCs is
limited, and although most patients show an initial response to treatment, upon relapse, this platinum
response rate progressively declines, and ultimately disappears [52,53]. These reasons illustrate the
great need for novel therapeutic strategies to overcome platinum resistance. Subsequently, therapeutic
targeting of the TGFβ pathway in ovarian tumors should be one of the options to be tested. Some
publications have already demonstrated the effectiveness of this treatment in ovarian cancer. For
example, a pre-clinical study by Liao and colleagues showed blocked tumor growth in an SK-OV3 cell
line transfected with nanoparticle-mediated soluble extracellular domain of the transforming growth
factor-β type II receptor (sTGFβRII) [54]. Our recent work concluded that TGFβ inhibition blocked
tumor growth in pre-clinical orthotopic models of ovarian cancer (PDX) [25]. It has recently been
reported that a combination of a TGFβ inhibitor and cisplatinum in ovarian cancer cell lines had a
stronger anti-proliferative effect than the additive effects of each treatment alone, and promoted tumor
regression in established parental and resistant ovarian cancer xenograft models [55]. Thus, inhibition
of the TGFβ pathway may enhance the treatment benefit of cisplatinum, which is the current standard
treatment for ovarian cancer patients.
Some clinical trials blocking the TGFβ signaling pathway in ovarian cancer are being
evaluated [56]. For example, a phase II study of high-risk stage III/IV ovarian cancer is underway that
features an adjuvant FANG™ vaccine, which downregulates TGFβ1 and 2. Two clinical studies are
being conducted in advanced solid tumors: a phase I study of anti-TGFβRII monoclonal antibody
IMC-TR1 (LY3022859) in patients with advanced solid tumors, and a phase I trial with the TGFβ
pathway inhibitor TEW 7197 in subjects with refractory solid tumors. Some TGFβ inhibitors are
already at the late stages of disease-specific clinical trials: phase I/II in combination with radiotherapy
and fresolimumab (TGFβ inhibitor) in non-small cell lung cancer and metastatic breast cancer. There
is also a phase III trial in glioblastoma with trabedersen (AP-12009), another with galunisertib
(LY2157299) [57], which is under clinical development in phase II studies of hepatocellular carcinoma,
and phase I trials in glioblastoma, hepatocellular carcinoma, pancreatic cancer and non-small cell
lung cancer.
7. Concluding Remarks
TGFβ signaling seems to play a role in ovarian physiology as well as acting as a tumor promoter
that controls proliferation in ovarian cancer. Although mutations in this pathway are rare in this tumor,
there are other mechanisms by which TGFβ, directly or indirectly, is associated with the promotion of
ovarian cancer cell proliferation. Further investigation and progress in delineating the mechanisms
involved in every specific ovarian tumor subtype is essential, given the heterogeneity of ovarian cancer
at the molecular level.
A therapeutic approach blocking TGFβ signaling in ovarian cancer would provide an opportunity
for these patients that takes into account the role that TGFβ plays in ovarian cancer proliferation.
A better knowledge of the molecular mechanisms is essential if we are to be able to provide optimal
patient stratification for these clinical assays. It is known that not all patients will respond in the same
way to some target therapies and, in the case of ovarian cancer, it is even more difficult, since there are
different histological subtypes with variable molecular characteristics.
Int. J. Mol. Sci. 2017, 18, 1658 7 of 10
Acknowledgments: This study was supported by research grants to Francesc Viñals from the Spanish Ministerio
de Economía y Competitividad (SAF2013-46063R), the Spanish Institute of Health Carlos III (ISCIII) and the
European Regional Development Fund (ERDF) under the Integrated Project of Excellence no. PIE13/00022
(ONCOPROFILE), and the Generalitat de Catalunya (2014SGR364). Work was supported by the Xarxa de Bancs de
Tumors de Catalunya, sponsored by Pla Director d’Oncología de Catalunya (XBTC), IDIBELL and PLATAFORMA
BIOBANCOS PT13/0010/0013. EAS is a recipient of a predoctoral fellowship from the Ministerio de Economía
y Competitividad.
Author Contributions: Elisenda Alsina-Sanchís, Agnès Figueras and Alvaro Lahiguera performed the
experiments; Marta Gil-Martín, Beatriz Pardo, Josep M. Piulats, Lola Martí, Jordi Ponce, Xavier Matias-Guiu
and Alberto Villanueva acquired data and managed patients; Elisenda Alsina-Sanchís, Marta Gil-Martín,
Josep M. Piulats, August Vidal and Francesc Viñals analyzed the data; Elisenda Alsina-Sanchís, Marta Gil-Martín
and Francesc Viñals wrote the paper.
Conflicts of Interest: The Catalan Institute of Oncology received an unrestricted grant from Roche to finance the
Pro Cure Programme (2015).
References
1. Berrino, F.; De Angelis, R.; Sant, M.; Rosso, S.; Bielska-Lasota, M.; Coebergh, J.W.; Santaquilani, M. Survival
for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: Results of the
eurocare-4 study. Lancet Oncol. 2007, 8, 773–783. [CrossRef]
2. Ferlay, J.; Parkin, D.M.; Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008.
Eur. J. Cancer 2010, 46, 765–781. [CrossRef] [PubMed]
3. Oberaigner, W.; Minicozzi, P.; Bielska-Lasota, M.; Allemani, C.; de Angelis, R.; Mangone, L.; Sant, M. Survival
for ovarian cancer in Europe: The across-country variation did not shrink in the past decade. Acta. Oncol.
2012, 51, 441–453. [CrossRef] [PubMed]
4. Kuhn, E.; Meeker, A.K.; Visvanathan, K.; Gross, A.L.; Wang, T.L.; Kurman, R.J.; Shih Ie, M. Telomere length
in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma. Mod. Pathol. 2011,
24, 1139–1145. [CrossRef] [PubMed]
5. Stewart, B.W.; Kleihues, P. World Cancer Report; IARC Press: Lyon, France, 2003.
6. Dubeau, L. The cell of origin of ovarian epithelial tumours. Lancet. Oncol. 2008, 9, 1191–1197. [CrossRef]
7. Prat, J. Ovarian carcinomas: Five distinct diseases with different origins, genetic alterations, and
clinicopathological features. Virchows. Arch. 2012, 460, 237–249. [CrossRef] [PubMed]
8. Kurman, R.J.; Shih Ie, M. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying
theory. Am. J. Surg. Pathol. 2010, 34, 433–443. [CrossRef] [PubMed]
9. Karnezis, A.N.; Cho, K.R.; Gilks, C.B.; Pearce, C.L.; Huntsman, D.G. The disparate origins of ovarian cancers:
Pathogenesis and prevention strategies. Nat. Rev. Cancer 2017, 17, 65–74. [CrossRef] [PubMed]
10. Medeiros, F.; Muto, M.G.; Lee, Y.; Elvin, J.A.; Callahan, M.J.; Feltmate, C.; Garber, J.E.; Cramer, D.W.;
Crum, C.P. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian
cancer syndrome. Am. J. Surg. Pathol. 2006, 30, 230–236. [CrossRef] [PubMed]
11. Lee, Y.; Miron, A.; Drapkin, R.; Nucci, M.R.; Medeiros, F.; Saleemuddin, A.; Garber, J.; Birch, C.; Mou, H.;
Gordon, R.W.; et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
J. Pathol. 2007, 211, 26–35. [CrossRef] [PubMed]
12. Karst, A.M.; Levanon, K.; Drapkin, R. Modeling high-grade serous ovarian carcinogenesis from the fallopian
tube. Proc. Natl. Acad. Sci. USA 2011, 108, 7547–7552. [CrossRef] [PubMed]
13. Kurman, R.J.; Shih, Ie.M. Molecular pathogenesis and extraovarian origin of epithelial ovarian
cancer–shifting the paradigm. Hum. Pathol. 2011, 42, 918–931. [CrossRef] [PubMed]
14. Terada, T. Endometrioid adenocarcinoma of the ovary arising in atypical endometriosis. Int. J. Clin.
Exp. Pathol. 2012, 5, 924–927. [PubMed]
15. Yuan Z, W.Y.; Cragun, J.M.; Chambers, S.K.; Zheng, W. Cell origin of endometriosis: Contribution by the
fallopian tube epithelium. Am. J. Clin. Exp. Obstet. Gynecol. 2013, 1, 37–42.
16. Eckert, M.A.; Pan, S.; Hernandez, K.M.; Loth, R.M.; Andrade, J.; Volchenboum, S.L.; Faber, P.; Montag, A.;
Lastra, R.; Peter, M.E.; et al. Genomics of ovarian cancer progression reveals diverse metastatic trajectories
including intraepithelial metastasis to the fallopian tube. Cancer Discov. 2016, 6, 1342–1351. [CrossRef]
[PubMed]
Int. J. Mol. Sci. 2017, 18, 1658 8 of 10
17. Bast, R.C., Jr.; Hennessy, B.; Mills, G.B. The biology of ovarian cancer: New opportunities for translation.
Nat. Rev. Cancer 2009, 9, 415–428. [CrossRef] [PubMed]
18. Vaughan, S.; Coward, J.I.; Bast, R.C., Jr.; Berchuck, A.; Berek, J.S.; Brenton, J.D.; Coukos, G.; Crum, C.C.;
Drapkin, R.; Etemadmoghadam, D.; et al. Rethinking ovarian cancer: Recommendations for improving
outcomes. Nat. Rev. Cancer 2011, 11, 719–725. [CrossRef] [PubMed]
19. Chandler, R.L.; Damrauer, J.S.; Raab, J.R.; Schisler, J.C.; Wilkerson, M.D.; Didion, J.P.; Starmer, J.; Serber, D.;
Yee, D.; Xiong, J.; et al. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis
through pro-tumorigenic inflammatory cytokine signalling. Nat. Commun. 2015, 6, 6118. [CrossRef]
[PubMed]
20. Moxley, K.M.; Wang, L.; Welm, A.L.; Bieniasz, M. Short-form Ron is a novel determinant of ovarian cancer
initiation and progression. Genes Cancer 2016, 7, 169–181. [PubMed]
21. Knight, P.G.; Glister, C. TGF-β superfamily members and ovarian follicle development. Reproduction 2006,
132, 191–206. [CrossRef] [PubMed]
22. Reader, K.L.; Gold, E. Activins and activin antagonists in the human ovary and ovarian cancer. Mol. Cell
Endocrinol. 2015, 415, 126–132. [CrossRef] [PubMed]
23. Chang, H.M.; Qiao, J.; Leung, P.C.K. Oocyte–somatic cell interactions in the human ovary—Novel role
of bone morphogenetic proteins and growth differentiation factors. Hum. Reprod. Update 2017, 23, 1–18.
[CrossRef] [PubMed]
24. Nilsson, E.; Doraiswamy, V.; Parrott, J.A.; Skinner, M.K. Expression and action of transforming growth factor
β (TGFβ1, TGFβ2, TGFβ3) in normal bovine ovarian surface epithelium and implications for human ovarian
cancer. Mol. Cell Endocrinol. 2001, 182, 145–155. [CrossRef]
25. Alsina-Sanchis, E.; Figueras, A.; Lahiguera, A.; Vidal, A.; Casanovas, O.; Graupera, M.; Villanueva, A.;
Viñals, F. The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing igf1r levels.
Int. J. Cancer 2016, 139, 1894–1903. [CrossRef] [PubMed]
26. Li, Q.; Pangas, S.A.; Jorgez, C.J.; Graff, J.M.; Weinstein, M.; Matzuk, M.M. Redundant roles of SMAD2 and
SMAD3 in ovarian granulosa cells in vivo. Mol. Cell Biol. 2008, 28, 7001–7011. [CrossRef] [PubMed]
27. Liu, Z.; Ren, Y.A.; Pangas, S.A.; Adams, J.; Zhou, W.; Castrillon, D.H.; Wilhelm, D.; Richards, J.S. Foxo1/3
and PTEN depletion in granulosa cells promotes ovarian granulosa cell tumor development. Mol. Endocrinol.
2015, 29, 1006–1024. [CrossRef] [PubMed]
28. Pangas, S.A.; Li, X.; Umans, L.; Zwijsen, A.; Huylebroeck, D.; Gutierrez, C.; Wang, D.; Martin, J.F.; Jamin, S.P.;
Behringer, R.R.; et al. Conditional deletion of SMAD1 and SMAD5 in somatic cells of male and female gonads
leads to metastatic tumor development in mice. Mol. Cell Biol. 2008, 28, 248–257. [CrossRef] [PubMed]
29. Tian, M.; Neil, J.R.; Schiemann, W.P. Transforming growth factor-β and the hallmarks of cancer. Cell. Signal.
2011, 23, 951–962. [CrossRef] [PubMed]
30. Helleman, J.; Jansen, M.P.; Burger, C.; van der Burg, M.E.; Berns, E.M. Integrated genomics of chemotherapy
resistant ovarian cancer: A role for extracellular matrix, TGFβ and regulating micrornas. Int. J. Biochem.
Cell Biol. 2010, 42, 25–30. [CrossRef] [PubMed]
31. Antony, M.L.; Nair, R.; Sebastian, P.; Karunagaran, D. Changes in expression, and/or mutations in TGF-β
receptors (TGF-β RI and TGF-β RII) and SMAD 4 in human ovarian tumors. J. Cancer Res. Clin. Oncol. 2010,
136, 351–361. [CrossRef] [PubMed]
32. Kaklamani, V.G.; Hou, N.; Bian, Y.; Reich, J.; Offit, K.; Michel, L.S.; Rubinstein, W.S.; Rademaker, A.; Pasche, B.
TGFBR1*6A and cancer risk: A meta-analysis of seven case-control studies. J. Clin. Oncol. 2003, 21, 3236–3243.
[CrossRef] [PubMed]
33. Parikh, A.; Lee, C.; Joseph, P.; Marchini, S.; Baccarini, A.; Kolev, V.; Romualdi, C.; Fruscio, R.; Shah, H.;
Wang, F.; et al. Microrna-181A has a critical role in ovarian cancer progression through the regulation of the
epithelial-mesenchymal transition. Nat. Commun. 2014, 5, 2977. [CrossRef] [PubMed]
34. Petrillo, M.; Zannoni, G.F.; Beltrame, L.; Martinelli, E.; DiFeo, A.; Paracchini, L.; Craparotta, I.; Mannarino, L.;
Vizzielli, G.; Scambia, G.; et al. Identification of high-grade serous ovarian cancer mirna species associated
with survival and drug response in patients receiving neoadjuvant chemotherapy: A retrospective
longitudinal analysis using matched tumor biopsies. Ann. Oncol. 2016, 27, 625–634. [CrossRef] [PubMed]
35. Henriksen, R.; Gobl, A.; Wilander, E.; Oberg, K.; Miyazono, K.; Funa, K. Expression and prognostic
significance of TGF-β isotypes, latent TGF-β 1 binding protein, TGF-β type I and type II receptors, and
endoglin in normal ovary and ovarian neoplasms. Lab. Investig. 1995, 73, 213–220. [PubMed]
Int. J. Mol. Sci. 2017, 18, 1658 9 of 10
36. Rodon, L.; Gonzalez-Junca, A.; Inda Mdel, M.; Sala-Hojman, A.; Martinez-Saez, E.; Seoane, J. Active creb1
promotes a malignant TGFβ2 autocrine loop in glioblastoma. Cancer Discov. 2014, 4, 1230–1241. [CrossRef]
[PubMed]
37. Gordinier, M.E.; Zhang, H.Z.; Patenia, R.; Levy, L.B.; Atkinson, E.N.; Nash, M.A.; Katz, R.L.; Platsoucas, C.D.;
Freedman, R.S. Quantitative analysis of transforming growth factor β 1 and 2 in ovarian carcinoma.
Clin. Cancer Res. 1999, 5, 2498–2505. [PubMed]
38. Do, T.V.; Kubba, L.A.; Du, H.; Sturgis, C.D.; Woodruff, T.K. Transforming growth factor-β1, transforming
growth factor-β2, and transforming growth factor-β3 enhance ovarian cancer metastatic potential by
inducing a SMAD3-dependent epithelial-to-mesenchymal transition. Mol. Cancer Res. 2008, 6, 695–705.
[CrossRef] [PubMed]
39. Gao, J.; Zhu, Y.; Nilsson, M.; Sundfeldt, K. TGF-β isoforms induce EMT independent migration of ovarian
cancer cells. Cancer Cell Int. 2014, 14, 72. [CrossRef] [PubMed]
40. Komiyama, S.; Kurahashi, T.; Ishikawa, M.; Tanaka, K.; Komiyama, M.; Mikami, M.; Udagawa, Y. Expression
of TGFSS1 and its receptors is associated with biological features of ovarian cancer and sensitivity to
paclitaxel/carboplatin. Oncol. Rep. 2011, 25, 1131–1138. [CrossRef] [PubMed]
41. Gold, L.I.; Jussila, T.; Fusenig, N.E.; Stenback, F. TGF-β isoforms are differentially expressed in increasing
malignant grades of HaCaT keratinocytes, suggesting separate roles in skin carcinogenesis. J. Pathol. 2000,
190, 579–588. [CrossRef]
42. Baldwin, R.L.; Tran, H.; Karlan, B.Y. Loss of c-Myc repression coincides with ovarian cancer resistance to
transforming growth factor β growth arrest independent of transforming growth factor β/SMAD signaling.
Cancer Res. 2003, 63, 1413–1419. [PubMed]
43. Jozan, S.; Guerrin, M.; Mazars, P.; Dutaur, M.; Monsarrat, B.; Cheutin, F.; Bugat, R.; Martel, P.; Valette, A.
Transforming growth factor β 1 (TGF-β 1) inhibits growth of a human ovarian carcinoma cell line (ovccr1)
and is expressed in human ovarian tumors. Int. J. Cancer 1992, 52, 766–770. [CrossRef] [PubMed]
44. Kohan-Ivani, K.; Gabler, F.; Selman, A.; Vega, M.; Romero, C. Role of dihydrotestosterone (dht) on TGF-β1
signaling pathway in epithelial ovarian cancer cells. J. Cancer Res. Clin. Oncol. 2016, 142, 47–58. [CrossRef]
[PubMed]
45. Bruchim, I.; Werner, H. Targeting IGF-1 signaling pathways in gynecologic malignancies. Expert. Opin.
Ther. Targets 2013, 17, 307–320. [CrossRef] [PubMed]
46. Bruna, A.; Darken, R.S.; Rojo, F.; Ocana, A.; Penuelas, S.; Arias, A.; Paris, R.; Tortosa, A.; Mora, J.;
Baselga, J.; et al. High TGF β-SMAD activity confers poor prognosis in glioma patients and promotes
cell proliferation depending on the methylation of the pdgf-b gene. Cancer Cell. 2007, 11, 147–160. [CrossRef]
[PubMed]
47. Dunfield, L.D.; Nachtigal, M.W. Inhibition of the antiproliferative effect of TGFβ by EGF in primary human
ovarian cancer cells. Oncogene 2003, 22, 4745–4751. [CrossRef] [PubMed]
48. Ji, M.; Shi, H.; Xie, Y.; Zhao, Z.; Li, S.; Chang, C.; Cheng, X.; Li, Y. Ubiquitin specific protease 22 promotes
cell proliferation and tumor growth of epithelial ovarian cancer through synergy with transforming growth
factor β1. Oncol. Rep. 2015, 33, 133–140. [CrossRef] [PubMed]
49. Eichhorn, P.J.; Rodon, L.; Gonzalez-Junca, A.; Dirac, A.; Gili, M.; Martinez-Saez, E.; Aura, C.; Barba, I.; Peg, V.;
Prat, A.; et al. Usp15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β
signaling in glioblastoma. Nat. Med. 2012, 18, 429–435. [CrossRef] [PubMed]
50. Al-Salihi, M.A.; Herhaus, L.; Macartney, T.; Sapkota, G.P. Usp11 augments TGF β signalling by
deubiquitylating Alk5. Open Biol. 2012, 2, 120063. [CrossRef] [PubMed]
51. Zhang, L.; Zhou, F.; Drabsch, Y.; Gao, R.; Snaar-Jagalska, B.E.; Mickanin, C.; Huang, H.; Sheppard, K.A.;
Porter, J.A.; Lu, C.X.; et al. Usp4 is regulated by Akt phosphorylation and directly deubiquitylates TGF-β
type I receptor. Nat. Cell. Biol. 2012, 14, 717–726. [CrossRef] [PubMed]
52. Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G. Molecular
mechanisms of cisplatin resistance. Oncogene 2012, 31, 1869–1883. [CrossRef] [PubMed]
53. Foley, O.W.; Rauh-Hain, J.A.; del Carmen, M.G. Recurrent epithelial ovarian cancer: An update on treatment.
Oncology (Williston Park) 2013, 27, 288–294. [PubMed]
54. Liao, S.; Liu, J.; Lin, P.; Shi, T.; Jain, R.K.; Xu, L. TGF-β blockade controls ascites by preventing abnormalization
of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin. Cancer Res. 2011, 17, 1415–1424.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1658 10 of 10
55. Gao, Y.; Shan, N.; Zhao, C.; Wang, Y.; Xu, F.; Li, J.; Yu, X.; Gao, L.; Yi, Z. Ly2109761 enhances cisplatin
antitumor activity in ovarian cancer cells. Int. J. Clin. Exp. Pathol. 2015, 8, 4923–4932. [PubMed]
56. Neuzillet, C.; Tijeras-Raballand, A.; Cohen, R.; Cros, J.; Faivre, S.; Raymond, E.; de Gramont, A. Targeting the
TGFβ pathway for cancer therapy. Pharmacol. Ther. 2015, 147, 22–31. [CrossRef] [PubMed]
57. Dituri, F.; Mazzocca, A.; Fernando, J.; Papappicco, P.; Fabregat, I.; De Santis, F.; Paradiso, A.; Sabbà, C.;
Giannelli, G. Differential inhibition of the TGF-β signaling pathway in hcc cells using the small molecule
inhibitor LY2157299 and the D10 monoclonal antibody against TGF-β receptor type II. PLoS ONE 2013,
8, e67109. [CrossRef]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
